ARTICLE | Clinical News
Symbicort regulatory update
January 27, 2017 4:34 AM UTC
AstraZeneca said FDA granted 6 months of pediatric exclusivity to Symbicort budesonide/formoterol. The product is approved to treat asthma in patients ages ≥12 and as maintenance treatment of chronic ...
BCIQ Company Profiles